Biocon's biosimilars enter global Phase-3 trials

Biocon today announced today that it has made clinical progress in its partnered programs with Mylan.


Dr Kiran Mazumdar, CMD, Biocon (Photo Courtesy:

The partnership has a strong portfolio of generic insulin analogs and biosimilars including Monoclonal Antibodies (MAbs) and recombinant proteins at various stages of development.


Two molecules Pegfilgrastim (PEG-G-CSF) and Adalimumab have entered global Phase-3 clinical trials. While the PEG-G-CSF trial is well underway the Adalimumab trial has been recently initiated, said the company in a statement.

In addition, the Phase-3 global clinical trial for Trastuzumab is progressing in more than 100 sites around the world. An initial ROW focused Phase-3 trial for Bevacizumab is also underway, said Biocon.

Generic Insulin Analogs


Previous 1 3 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email